Biome Australia Limited
ABN: 51 627 364 014

16 Dover Street, Cremorne VIC 3121
+61 3 9017 5800 | www.biomeaustralia.com

FOR IMMEDIATE RELEASE

Satisfaction of Listing Conditions



Melbourne, Victoria, 30 November 2021 – complementary medicines company, Biome Australia Limited (**Biome Australia**) confirms that it has satisfied each of the Conditions to Admission as detailed in the Admission Decision dated 18 November 2021.

Biome Australia provides the following pre-quotation disclosures:

The conversion of Performance Rights and issue of Options

The issue of the following securities:

Securities	Detail	Number
Ordinary Shares	The 11,175,907 Performance Rights have been converted into 11,175,907 Ordinary Shares.	11,175,907 Ordinary Shares
Options	2,131,404 options have been issued with an exercise price of $0.30 exercisable for a period of three years from the date of issue to a controlled entity of Canaccord Genuity (Australia) Limited	2,131,404 Options
	2,131,404 options with an exercise price of $0.40 exercisable for a period of four years from the date of issue to a controlled entity of Canaccord Genuity (Australia) Limited	2,131,404 Options

ASX imposed escrow

The following Shares and Options are subject to ASX restrictions:

Security	Number	ASX restriction period
Ordinary Shares	39,359,545	24 months commencing on the date of official quotation of the ordinary shares in Biome Australia
Ordinary Shares	718,842	Ending on 11 January 2022
	415,582	Ending on 1 March 2022
	506,336	Ending on 12 March 2022
	16,848	Ending on 19 March 2022
	126,290	Ending on 26 March 2022
	89,856	Ending on 29 March 2022
	251,595	Ending on 26 April 2022
	336,958	Ending on 13 May 2022
	224,638	Ending on 1 June 2022
	112,319	Ending on 11 June 2022
	28,107	Ending on 15 June 2022
	224,638	Ending on 16 June 2022
	188,697	Ending on 18 June 2022
	224,638	Ending on 21 June 2022
	494,203	Ending on 22 June 2022
	1,120,652	Ending on 23 June 2022

	224,638	Ending on 28 June 2022
	112,319	Ending on 30 June 2022
	224,638	Ending on 19 July 2022
	560,696	Ending on 20 July 2022
	22,464	Ending on 26 July 2022
	33,696	Ending on 27 July 2022
	44,928	Ending on 29 July 2022
	20,218	Ending on 30 July 2022
	112,319	Ending on 4 August 2022
	1,213,498	Ending on 5 August 2022
	65,236	Ending on 6 August 2022
	134,783	Ending on 9 August 2022
	151,631	Ending on 10 August 2022
	60,653	Ending on 11 August 2022
	101,088	Ending on 12 August 2022
	22,464	Ending on 13 August 2022
	56,160	Ending on 15 August 2022
	179,801	Ending on 16 August 2022
	325,726	Ending on 18 August 2022
	381,885	Ending on 31 August 2022
Options	4,401,865	24 months commencing on the date of official quotation of the ordinary shares in Biome Australia

Voluntary escrow

The following Shares are subject to voluntary escrow:

Security	Number	ASX restriction period
Ordinary Shares	47,470,727	Ending 6 months following the date of quotation, being 31 May 2022

Biome Australia's capital deck

The capital deck of Biome Australia is as follows:

Security	Number
Ordinary Shares	199,909,857 Ordinary Shares. This is made up of: • 148,733,950 Existing Shares; • 40,000,000 Shares issued under the Offer; and • 11,175,907 Shares issued on conversion of Performance Rights.
Options	17,261,659 Options. This is made up of: • 12,998,851 Existing Options; and • 4,262,808 Options issued to a controlled entity of the Lead Manager, Canaccord Genuity (Australia) Limited.

Authorised for release by the Board of Biome Australia Limited.

About Biome Australia Limited

Biome Australia

Biome Australia develops, licenses, commercialises innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics®.

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

Biome also develops, licenses and distributes a scientifically formulated, organic nutraceutical range, Activated Nutrients® and a sports performance and recovery range, Activated X Performance®, which is made exclusively for professional athletes.

For more information visit: www.biomeaustralia.com

For further information, please contact:

George Lazarou
Company Secretary
T: (03) 8617 8014
E: george@activated.co